Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$23.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 48.92% year-over-year to -$23.7 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 33.2% increase from a year earlier, with the FY2025 full-year figure at $16.2 million, down 24.04% from the prior year.
• Change in Accured Expenses retreated to -$23.7 million in Q1 2026 per VRDN's latest filing, from $21.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.3 million in Q4 2025 and bottomed at -$23.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $3.9 million (2024), against an average of $1.5 million.
• Across the five-year window, Change in Accured Expenses surged 433.33% in 2023 and slumped 1679.08% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $6.0 million in 2022, then dropped by 24.48% to $4.5 million in 2023, then soared by 138.05% to $10.8 million in 2024, then soared by 97.5% to $21.3 million in 2025, then plunged by 211.12% to -$23.7 million in 2026.
• Per Business Quant, the three latest VRDN Change in Accured Expenses figures stand at -$23.7 million (Q1 2026), $21.3 million (Q4 2025), and $4.6 million (Q3 2025).